Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.39 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629810 | 0.90 | CHRNA7 (0.39) | CHRNA7SNRNP200REV1HDAC6CYP19A1 | |
| SCHEMBL630295 | 0.85 | HDAC6 (0.38) | CHRNA7SNRNP200REV1HDAC6CYP19A1 | |
| SCHEMBL630191 | 0.76 | CHRNA7 (0.36) | CHRNA7SNRNP200HDAC6CYP19A1CYP11B1 | |
| SCHEMBL630286 | 0.73 | KDM4E (0.38) | CHRNA7REV1 | |
| SCHEMBL630221 | 0.70 | PTPN1 (0.49) | CHRNA7SNRNP200CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL629885 | 0.69 | KDM4E (0.36) | HDAC6PDE4B | |
| SCHEMBL3927311 | 0.68 | CYP19A1 (0.36) | CHRNA7CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL647698 | 0.67 | CHRNA7 (0.34) | CHRNA7MAPK14CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL647136 | 0.67 | CHRNA7 (0.34) | CHRNA7CYP19A1CYP11B1CYP11B2PDE4B | |
| SCHEMBL647168 | 0.67 | CHRNA7 (0.34) | CHRNA7CYP19A1CYP11B1CYP11B2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | CHRNA7 4601/4885SNRNP200 4186/4885REV1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.